Severity
Moderate
FDA Drug recall · Reported February 18, 2026
Presence of Foreign substance - potential presence of metal particulate matter
F.h. Investments, Inc. (dba Asteria Health) recalled Testosterone 75mg, Anastrozole 4mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, B… - a moderate-severity action.
Testosterone 75mg, Anastrozole 4mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, B… was recalled by F.h. Investments, Inc. (dba Asteria Health) in February 18, 2026. Reason: Presence of Foreign substance - potential presence of metal particulate matter. Check the official notice for the remedy. Verify recall #D-0327-2026 with the FDA Drug before acting.
The recall
F.h. Investments, Inc. (dba Asteria Health) issued this moderate-severity FDA Drug recall-Presence of Foreign substance - potential presence of metal particulate matter.
Sourced from official FDA Drug enforcement records. Verify recall #D-0327-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0327-2026) was formally reported on February 18, 2026, with the manufacturer initiating the action on January 26, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. F.h. Investments, Inc. (dba Asteria Health) is listed as the recalling firm, operating out of Birmingham, AL. Federal records list the affected scope as 670 pellets.
The documented reason for this recall is: Presence of Foreign substance - potential presence of metal particulate matter Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
670 pellets
Related Recalls
6
5 from same agency
Testosterone 75mg, Anastrozole 4mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-4079-32.
Presence of Foreign substance - potential presence of metal particulate matter
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0327-2026 |
| Date reported | February 18, 2026 |
| Date initiated | January 26, 2026 |
| Recalling firm | F.h. Investments, Inc. (dba Asteria Health) |
| Firm location | Birmingham, AL |
| Affected scope | 670 pellets |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 18, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.